摘要
阿立哌唑已广泛应用于精神分裂症的治疗,其智能制剂和长效注射剂的开发可以在一定程度上提高患者依从性,近年来得到了广泛的关注。本研究通过检索相关国外审评报告和文献,结合《第三批鼓励仿制药品目录》中阿立哌唑长效注射剂收录情况,分析了国内外上市的阿立哌唑智能制剂和长效注射剂,对其药学研究进行探讨,重点关注处方工艺和质量控制等研究,为其仿制药研究开发提供科学参考和依据。
Aripiprazole drug products have been used widely for treatment of schizophrenia.The digital medicine and long-acting injections of aripiprazole have received widespread attention in recent years,which can improve patient compliance to some extent.Based on literature investigation,combined with analysis long-acting injections of aripiprazole in China‘Encourage generic drug catalogue(third batch)',theapproval cases were summarized,and thepharmaceutical considerations were put forward in terms formulation,manufacturing process and quality control,aimed to provide scientific reference for research and development of such drugs.
作者
司晓菲
唐谦
袭辰辰
姜典卓
SI Xiao-fei;TANG Qian;XI Chen-chen;JIANG Dian-zhuo(Center for Drug Evaluation,National Medical Products Administration,Bejing 100076,China;Zhejiang Center for Drug&Cosmetic Evaluation,Hangzhou 310012,Zhejiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2024年第10期1535-1540,共6页
The Chinese Journal of Clinical Pharmacology
基金
浙江省软科学研究计划基金资助项目(2023C35G1481898)。
关键词
阿立哌唑
智能制剂
长效注射剂
鼓励仿制药品目录
处方工艺
质量控制
药学研究
aripiprazole
digital medicine
long-acting injection
China encourage generic drug catalogue
formulation and manufacturing process development
quality control
pharmaceutical research